Comparison of tear proteomic and neuromediator profiles changes between small incision lenticule extraction (SMILE) and femtosecond laser-assisted in-situ keratomileusis (LASIK)

Yu-Chi Liu a,b,c,⇑, Gary Hin-Fai Yama,d, Molly Tzu-Yu Lin a, Ercia Teo a, Siew-Kwan Koh e, Lu Deng f, Lei Zhou c,e,g, Louis Tong b,c,g,h, Jodhbir S. Mehta a,b,c

a Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore
b Department of Cornea and External Eye Disease, Singapore National Eye Centre, Singapore
c Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore
d Department of Ophthalmology, University of Pittsburgh, PA, USA
e Ocular Proteomics, Singapore Eye Research Institute, Singapore
f Department of Statistics and Applied Probability, Faculty of Science, National University of Singapore, Singapore
g Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
h Ocular Surface Group, Singapore Eye Research Institute, Singapore

GRAPHICAL ABSTRACT

Tear proteomic profiles in LASIK in comparison with SMILE over time

ARTICLE INFO

Article history:
Received 16 July 2020
Revised 29 October 2020
Accepted 1 November 2020
Available online 5 November 2020

Keywords:
Tear
Proteomics
Neuromediators
Small incision lenticule extraction

ABSTRACT

Introduction: The tear proteomics and neuromediators are associated with clinical dry eye parameters following refractive surgery.
Purpose: To investigate and compare the tear proteomic and neuromediator profiles following small incision lenticule extraction (SMILE) versus laser-assisted in-situ keratomileusis (LASIK).
Methods: In this randomized controlled trial with paired-eye design, 70 patients were randomized to receive SMILE in one eye and LASIK in the other eye. Tear samples were collected preoperatively, and 1 week, 1, 3, 6 and 12 months postoperatively, and were examined for protein concentration changes using sequential window acquisition of all theoretical fragment ion mass spectrometry (SWATH-MS). The data were analyzed with DAVID Bioinformatics Resources for enriched gene ontology terms and over-represented pathways. Tear neuromediators levels were correlated with clinical parameters.

⇑Corresponding author at: The Academia, 20 College Road, Level 6, Singapore 169856, Singapore.
E-mail address: liuchiy@gmail.com (Y.-C. Liu).

https://doi.org/10.1016/j.jare.2020.11.001
2090-1232/© 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Laser-assisted in-situ keratomileusis
Dry eye

Results: Post-SMILE eyes had significantly better Oxford staining scores and tear break-up time (TBUT) than post-LASIK eyes at 1 and 3 months, respectively. Tear substance P and nerve growth factor levels were significantly higher in the LASIK group for 3 months and 1 year, respectively. SMILE and LASIK shared some similar biological responses postoperatively, but there was significant up-regulation in leukocyte migration and wound healing at 1 week, humoral immune response and apoptosis at 1 month, negative regulation of endopeptidase activity at 3 to 6 months, and extracellular structure organization at 1 year in the post-LASIK eyes. Tear mucin-like protein 1 and substance P levels were significantly correlated with TBUT ($r = -0.47, r = -0.49$, respectively).

Conclusion: Significant differences in the tear neuromediators and proteomics were observed between SMILE and LASIK, even though clinical dry eye signs have subsided and became comparable between 2 procedures.

© 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Small incision lenticule extraction (SMILE) has become a viable alternative to laser-assisted in situ keratomileusis (LASIK) for the refractive correction of myopia and myopic astigmatism [1]. Due to the small incision in SMILE, as opposed to a circumferential flap in LASIK, the impact on the ocular surface is expected to be less. A systematic review reported that the tear breakup time (TBUT) and ocular surface disease index (OSDI) scores were significantly better in SMILE than LASIK 6 months postoperatively [2]. A non-randomized comparative study showed that at 6 months postoperatively, 80% of patients in the SMILE group did not use any topical lubricants versus 57% in the LASIK group, with 20% of the LASIK group needing daily and frequent use of tear substitutes or even gels versus none of the patients in the SMILE group [3].

The risk factors for dry eye disease following refractive surgery are multifactorial. Pathophysiological mechanisms include corneal denervation, goblet cell loss, meibomian gland dysfunction, and ocular surface inflammation [4]. Ocular surface damage triggers an inflammatory response and subsequent production of cytokines such as tumor necrosis factor, interleukin (IL)-1, growth factors, free radicals, adhesion molecules and proteolytic enzymes [5]. Zhong et al. evaluated the early changes of tear mediators after SMILE versus femtosecond lenticule extraction (FLEx) and found that the SMILE group had lower expression of tear tumor growth factor (TGF)-a and IL-1 at 1 month postoperatively [6]. The same authors also investigated the tear mediators in SMILE versus LASIK, and lower IL-6 tear level was noted in SMILE at 1 month [7]. These studies, however, are limited by their short follow-up time (up to postoperative 3 months), small patient number, and data from non-paired eyes that would introduce inter-subject variability.

Tear neurotransmitters and neuropeptides that mediate neurogenic inflammation also play an important role in postoperative dry eye diseases. Surgical incisions and laser exposure activate stromal keratocytes to undergo a wound healing response and trigger neurogenic inflammation [8]. The key mediators of neurogenic inflammation include tachykinins, calcitonin gene-related peptide (CGRP), substance P, and proinflammatory cytokines especially IL-6. CGRP and substance P act directly on vascular endothelial and smooth muscle cells, and induce vasodilation as well as increased vascular permeability, resulting in the recruitment and attraction of immune cells to the corneal wound site [9]. In patients with chronic idiopathic dry eyes, the tear CGRP level was decreased, and this was associated with increased corneal staining [10]. Nerve growth factor (NGF) is another neuropeptide that can accelerate corneal epithelial healing and tract repair, as well as induce keratocyte migration and facilitate corneal nerve regeneration. Increased tear NGF levels have been observed in LASIK patients at 6 months postoperatively [11].

To decipher the changes in protein expression in a biological process, an approach using advanced quantitative proteomics, such as isobaric tags for relative and absolute quantitation (iTRAQ) or sequential window acquisition of all theoretical fragment mass spectra (SWATH-MS), has been used recently [12]. The advantages of SWATH-MS include its higher reproducibility especially when dealing with a large cohort, the ability to pick up signals from low abundant peptides or proteins, and the capacity to allow for comparisons across multiple time points, especially when the sample quantity is limited, such as tear samples [13].

In the present study, we investigated the longitudinal changes of tear proteome and neuromediators over 1 year, using the SWATH technique, in patients who have undergone SMILE and LASIK. A randomized controlled trial (RCT) with paired-eye design was used to ensure more precise comparisons, by eliminating the inter-individual and inter-eye variation. The results of tear proteomics and neuromediators were also correlated with clinical dry eye parameters.

Methods

Patients and surgical procedures

This RCT (NCT01216475) included 70 patients randomized to undergo SMILE in one eye and femtosecond laser-assisted LASIK in the other eye at the Singapore National Eye Center between August 2012 and November 2016, with the inclusion and exclusion criteria detailed in Supplementary Table 1. The random allocation sequence was generated by a computer with no blocks or restrictions, and implemented by concealing the number-coded surgery within sealed envelopes until just before the procedure. The right eye was always operated first, hence this was the eye to which the random allocation applied [14]. SMILE procedure was performed as previously described [1,14]. In brief, a S-sized curved interface cone was applied, and the femtosecond laser (Visumax; Carl Zeiss, Jena, Germany) with the power set at 145 mJ, was used to create the following planes: posterior surface of the lenticule, anterior surface of the lenticule, which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior cap, and a 2.8 mm vertical circumferential incision placed at 120° [15]. The cap thickness was 120 μm, cap diameter was 7.5 mm, optical zone was 6.5 mm, and the side-cut angle was at 90°. A SMILE dissector (ASICO, Westmont, IL, USA) was used for the dissection of the anterior and posterior planes of lenticule, followed by the removal of the lenticule. For the LASIK procedure, a superiorly-hinged, 120 μm–thick flap was created using the Visumax femtosecond laser. Excimer laser ablation was then performed the WaveLight EX500 excimer laser (Alcon Laboratories, Inc, Fort Worth, TX). After ablation, the flap was carefully repositioned. All the procedures were performed under topical anesthesia by the same refractive surgeon. The postoperative regimen for SMILE and LASIK groups were identical, consisting of topical preservative-free dexamethasone and moxifloxacin, each 3 hourly
for a week then 4 times a day for 2 weeks. Artificial tears (Tears Naturale Free; AlconLaboratories, Kaysersberg, France) were also prescribed, and the dosage was the same for the first 3 months for both eyes, afterwards they were applied ad libitum. Approval for the study was granted by the institutional review board of SingHealth, Singapore (2011/109/A), and the study was conducted in accordance to the Declaration of Helsinki.

Dry eye assessments

Dry eye assessments were performed preoperatively, and 1 week, and 1, 3, 6, 12 months postoperatively for all patients. The assessments were comprised of Schirmer’s I test (without anesthesia, mm/5 min), ocular surface fluorescein staining (Oxford score; 0: absent, 5: severe), and TBUT. In Schirmer’s test, after the wetted area of Schirmer’s strip was measured, the strips were stored at −80 °C until the day of analysis. For TBUT, the right eye was evaluated first followed by the left eye, by placing a single fluorescein strip over the inferior tear meniscus after shaking off a small drop of normal saline. The time between eye opening and the first appearance of a dry spot on the cornea was recorded as the TBUT [16]. Three consecutive tests were performed and the average value was taken.

![Fig. 1. Volcano plot showing the fold changes and p values comparing the proteomic data of different postoperative time points (A: 1 week, B: 1 month, C: 3 months, D: 6 months, E: 12 months) with that of baseline in SMILE. Red dots indicate significantly up-regulated proteins (FC > 1.5 and P < 0.05, i.e. log2 FC > 0.58 and -log2 P > 4.3), and blue dots indicate significantly down-regulated proteins (FC < 0.67 and P < 0.05, i.e. log2 FC < -0.58 and -log2 P > 4.3).]

![Fig. 2. Chord plots illustrating GO analysis of top 10 up-regulated and down-regulated proteins and associated pathways in SMILE surgery at 1 week (A), 1 month (B), 3 months (C) and 12 months (D), in comparison to the baseline. Chord plots represent a circular dendrogram of the clustering of the expression profiles. Log FC: log2 (fold-changes).]
Table 1
Top 10 up-regulated and down-regulated tear proteins in post-SMILE eyes at different time points postoperatively.

| 1 week | 1 month | 3 months | 6 months | 12 months |
|--------|---------|----------|----------|-----------|
| Protein Name | log₂ FC | P Value | Protein Name | log₂ FC | P Value | Protein Name | log₂ FC | P Value | Protein Name | log₂ FC | P Value |
| Apolipoprotein C3 (APOC3) | 3.9943 | 0.0050 | Ig lambda variable 2-11 (IGLV2-11) | 2.3345 | 0.0430 | Mucin-like protein 1 (MUC1) | 3.3505 | 0.0017 |
| Glutamate/ proline-tRNA ligase (EPRS) | 3.0457 | 0.0138 | Cystatin D (CST5) | 1.9240 | 0.0024 | Serum amyloid A4 (SAA4) | 2.1507 | 0.0458 |
| Apolipoprotein E (APOE) | 2.8546 | 0.0187 | Apolipoprotein E (APOE) | 2.2432 | 0.0126 | Cystatin D (CST5) | 2.1010 | 0.0497 |
| Serum paraoxonase (PON1) | 2.5651 | 0.0297 | Serum paraoxonase (PON1) | 1.9528 | 0.0159 | Inter-α-trypsin inhibitor heavy chain H1 (ITIH1) | 1.3885 | 0.0161 |
| Complement C1r (C1R) | 2.3810 | 0.0399 | Fibronectin 1 (FN1) | 1.8373 | 0.0204 | Peptidyl-glycine α-amidating mono-oxygenase (PAM) | 1.3818 | 0.0307 |
| Fibronectin 1 (FN1) | 2.2581 | 0.0086 | Chitinase domain containing 1 (CHI1) | 1.8304 | 0.0098 | Peptidyl-glycine α-chains (C4BPA) | 1.2190 | 0.0119 |
| Mucin-like protein 1 (MUC1) | 2.0267 | 0.0032 | C4b-binding protein α-chain (C4BPA) | 1.8340 | 0.0098 | Annexin A11 (ANXA11) | 1.2210 | 0.0406 |
| Ig lambda variable 2-18 (IGLV2-18) | 1.7282 | 0.0059 | Serum paraoxonase (PON1) | 1.7841 | 0.0256 | Inter-α-trypsin inhibitor heavy chain H1 (ITIH1) | 1.1360 | 0.0340 |
| α2-antiplasmin (SERPINF2) | 1.6716 | 0.0300 | Keratin 13 (KRT13) | 1.7798 | 0.0260 | Tumor protein D52 (TPD52) | 1.4155 | 0.0206 |
| C4b-binding proteins chain (C4BPA) | 1.4591 | 0.0043 | Keratin 4 (KRT4) | 1.5519 | 0.0121 | N-Acylsphingosine amidohydrolase 1 (ASAH1) | 1.2925 | 0.0396 |

**Down-regulated proteins**

| 1 | Peptidyl-prolyl cis-trans isomerase C (PPIA) | −6.4759 | 0.0001 | Thymidine Phosphorylase (TPMP) | −1.7024 | 0.0001 | Tubulin α4A (TUBA4A) | −4.4151 | 0.0066 |
| 2 | Superoxide dismutase 3 (SOD3) | −1.9301 | 0.0024 | ADP ribosylation Factor 5 (ARF5) | −1.6447 | 0.0490 | Aldo-keto reductase 7A2 (AKR7A2) | −2.0444 | 0.0089 |
| 3 | Myeloblastin (PRTN3) | −1.4818 | 0.0180 | Peroxiredoxin 3 (PRDX3) | −1.5867 | 0.0397 | Histone H1.4 (HIST1H4E) | −1.4605 | 0.0364 |
| 4 | Scc substrate cortactin (CTTN) | −1.4813 | 0.0075 | Actin related protein 3 (ACTR3) | −1.3065 | 0.0559 | Actin-related protein 3 (ACTR3) | −1.4155 | 0.0206 |
| 5 | Tryptophan–tRNA ligase (WARS) | −1.4618 | 0.0384 | Heat shock protein 90 αA member 1 (HSP90AA1) | −1.2742 | 0.0061 | Tumor protein D52 (TPD52) | −1.3124 | 0.0103 |

Yu-Chi Liu, Gary Hin-Fai Yam, Molly Tzu-Yu Lin et al. Journal of Advanced Research 29 (2021) 67–81

Journal of Advanced Research 29 (2021) 67–81
Table 1 (continued)

| Protein Name | log FC | P Value |
|--------------|--------|---------|
| Plasminogen activator inhibitor 2 (SERPINB2) | 0.9677 | 0.0266 |
| Cadherin-1 (CDH1) | 1.0685 | 0.0062 |
| Cystatin-A (CSTA) | 1.2211 | 0.0413 |
| Heat shock protein 90 (HSP90AA1) | 3.4600 | 0.0048 |

Quantitative proteomics

Thirty pairs of tear samples selected randomly for proteomics analysis. Tear proteins from finely cut Schirmer’s strip were extracted by ammonium bicarbonate (50 mM, 100 µl per strip; Sigma-Aldrich, St. Louis, MO, USA) at 1300 rpm, room temperature (23 °C) for 1 h, and the protein concentration was measured. Protein samples (100 µg) were applied for SWATH-MS and a spectral library was established as previously described [17,18]. The digested samples were reconstituted in loading buffer (0.1% formic acid, 2% acetonitrile in water), and iRT standard (Biognosys, Switzerland) was spiked. Sample analysis was performed using an Ultimate 3000 nanoLC system ( Dionex, Thermo Fisher Scientific, MA, USA) coupled with AB Sciex 5600 triple TOF (AB Sciex, Framingham, MA, USA) as previously reported [18,19].

Enzyme-linked immunosorbent assay (ELISA)

Forty patients were randomly selected for neuromediator analysis. Tear proteins from each Schirmer strip sample were eluted by submerging finely cut Schirmer’s strips into 200 µl elution buffer containing 0.55 M NaCl, 0.33% Tween-20, 0.55% bovine serum albumin and protease inhibitor, with brief sonication and agitation at 450 rpm for 17 h at 4 °C. The elutes were centrifuged and clear supernatants were collected for protein assay, using a Micro BCA Protein Assay Kit (Pierce Biotechnology, Inc. MA, USA). ELISA for CGRP, NGF and Substance P were performed per manufacturers’ instructions (CGRP ELISA kit from Phoenix Pharmaceuticals, Runcon, UK; NGF and Substance P ELISA kits from R&D Systems, Minneapolis, USA). Each eluted tear sample was diluted 4x, 4x, and 1.5x for Substance P, CGRP and NGF, respectively, with individual assay diluent to a final volume of 50 µl per well. All samples were evaluated in duplicate per analyte per run. Optical density (OD) was read at 450 nm using a microplate reader, and OD reading at 540 nm was set as background. The concentrations were interpolated from the standard curve.

Differential protein expression and pathway analyses

SWATH proteomics data were processed with Spectronaut (Biognosys, Schlieren, Switzerland). The relative quantitation data in terms of ratio was generated, and they included (1) post-SMILE data at different time points versus preoperative data; (2) post-LASIK data at different time points versus preoperative data; and (3) pairwise LASIK versus SMILE ratios at different time points. The differentially expressed proteins were determined with linear models for microarray data (LIMMA) algorithm [20] with fold changes (FC) > 1.50 or < 0.67, i.e. the log₂ FC > 0.58 or < -0.58, and P values < 0.05. Only proteins that exhibited consistent changes among all 30 sample pairs were reported and used for pathway analyses. Proteins with statistically significant changes (P < 0.05) without the concordant changes in all 30 SMILE/LASIK pairs were excluded. Gene Ontology (GO) term analysis to identify enriched biological themes was done by inputting database to web-based DAVID Bioinformatics Resources v6.8 (NIAID, NIH, USA) [21]. Adjusted Benjamini P values were calculated by Modified Fisher Exact test with the smaller P values representing higher chance of enrichment. Bioinformatics analysis was performed using Metascape [22]. The differentially regulated proteins were also analysed using Reactome Knowledgebase [23] to explore the functional relationship and their contribution in the biological process network. Custom R scripts with R 64-bit version 3.4.0 [24] was used to generate the plots to illustrate the results of protein expression and GO analysis.
**Statistical analysis**

All data were expressed as mean ± standard deviation. The required sample size was calculated based on the pilot data of the clinical parameter, which is the primary outcome of the study (6-months TBUT). A sample size of 62 eyes per arm, with a power of ≥ 80% and at a 5% significance, was sufficient to detect the difference between the SMILE and LASIK groups. Considering a dropout rate of 10%, a total of 70 patients were recruited. A paired t-test was used to compare the SMILE and LASIK groups, as well as preoperative and postoperative data. The correlation analysis was performed with a Spearman (ordinal variables) or Pearson test (continuous variables). The statistical analysis was carried out using STATA (STATACorp, College Station, TX, USA), and a P < 0.05 without adjusting for multiplicity was considered as significant.

**Results**

**Patient characteristics**

The mean age at the time of surgery was 27.6 ± 5.1 years (female: male = 45:25). The preoperative spherical equivalent was −5.3 ± 1.8 D and −5.2 ± 1.7 D for the SMILE and LASIK groups, respectively (P = 0.88). All the patients completed their follow-up visits for postoperative 3 months, and there were 4 and 6 patients who lost the follow up at 6 and 12 months, respectively.

**Clinical dry eye assessments**

All dry eye parameters were statistically comparable between 2 groups before the surgery. After surgery, the SMILE group had significantly better TBUT than the LASIK group at 1 week (8.4 ± 3.2 versus 6.1 ± 2.7 s; P = 0.0028), 1 month (9.3 ± 2.6 versus 7.0 ± 2.3 s; P < 0.001) and 3 months (10.0 ± 2.6 versus 8.3 ± 3.2 s; P = 0.011). The TBUT was recovered to the preoperative level at 6 months in post-SMILE eyes, whereas impaired TBUT was still noted at 12 months in post-LASIK eyes (Supplementary Fig. 1A). The Oxford score was significantly worse in the LASIK than SMILE group at 1 week (0.51 ± 0.28 versus 0.87 ± 0.33; P = 0.03) and 1 month (0.24 ± 0.19 versus 0.48 ± 0.11; P = 0.04), but not thereafter (Supplementary Fig. 1B). There was no significant difference between 2 groups in the Schirmer I test at all time points (Supplementary Fig. 1C). For the ocular surface staining and Schirmer’s test evaluation, a significant difference was noted at 1 week in post-SMILE eyes, and at 1 week and 1 month in post-LASIK eyes, in comparison with preoperative level.

**Proteomic analysis**

SWATH analysis identified and quantified an average of 541 ± 46 proteins with 95% confidence for the whole dataset.

**Post-SMILE tear protein changes**

The number and fold change of differentially abundant proteins following SMILE over time was illustrated in Fig. 1. In the early postoperative period (1 week and 1 month), immunoglobulin lambda variable 2–18 (IGLV2-18) that is involved in complement activation (log₂FC = 1.73; 1 week), apolipoprotein C3 (APOC3) that is involved in complement and coagulation cascades (log₂FC = 3.99 at 1 week and log₂FC = 2.97 at 1 month), APOE (log₂FC = 2.85 at 1 week, log₂FC = 2.24 at 1 month) and fibrinectin 1 (FN1, log₂-FC = 2.26 at 1 week, log₂FC = 1.95 at 1 month) that are related to acute inflammation, phagocytosis, and fibrotic responses, were significantly up-regulated (Fig. 2A, B; Table 1). At 3 months, up-regulated IGLV2-11 (log₂FC = 2.46), cystatin D (CST5, log₂FC = 2.00), and mucin-like 1 (MUC1, log₂FC = 1.94) were detected, and they are linked to the process of adaptive immune, immunoglobulin production and endopeptidase activities (Fig. 2C). Elevated APOC3 level was still noted at 6 months (log₂FC = 6.13), as well as serum amyloid A4 (SAA4; log₂FC = 2.15) and immunoglobulin heavy constant gamma 3 (IGHG3; log₂FC = 1.52) that all relate to chronic immunological responses. The complement responses subsided thereafter, and proteins involved in the endopeptidase activity (MUC1, CST5 and interleukin (IL)-19), wound healing (chitinase domain-containing protein 1, CHID1), protein folding, and response to the toxic substance were significantly up-regulated (Fig. 2). Submaxillary gland androgen-regulated protein 3A (SMR-3A) was significantly down-regulated (log₂FC = −3.21) at 3 months. Table 1 lists the differentially regulated proteins over time after SMILE.

**Post-LASIK tear protein changes**

The number and fold change of up-regulated and down-regulated proteins following LASIK over time were illustrated in Fig. 3. In the early post-LASIK period (1 week and 1 month), various immunoglobulin proteins (IGLV6-57, IGLV8-61, immunoglobulin kappa variable (IGKV)1–27, IgkV3D-15) were significantly up-regulated, indicating complement activation and immunoglobulin production (Table 2). Apoptotic signalling pathway (heat shock protein (HSP)A13; log₂FC = 2.82) and endopeptidase activity

---

**Fig. 3.** Volcano plot presenting the fold changes and p values comparing the proteomic data of different postoperative time points (A: 1 week, B: 1 month, C: 3 months, D: 6 months, E: 12 months) with that of baseline in LASIK. Red dots indicate significantly up-regulated proteins (FC > 1.5 and P < 0.05, i.e. log₂FC > 0.58 and -log₂P > 4.3), and blue dots indicate significantly down-regulated proteins (FC < 0.67 and P < 0.05, i.e. log₂ FC < −0.58 and -log₂P > 4.3).
Table 2
Top 10 up-regulated and down-regulated tear proteins in post-LASIK eyes at different time points postoperatively.

| Up-regulated proteins | 1 week | 1 month | 3 months | 6 months | 12 months |
|-----------------------|--------|---------|----------|----------|----------|
| Protein Name          | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value |
| Heat shock protein A13 (HSPA13) | 2.8282 | 0.0160 | Apolipoprotein C1 (APOC1) | 2.2720 | 0.0436 | Ig kappa variable 3D-15 (IGKV3D-15) | 3.3966 | 0.0000 | Ig kappa variable 1-6 (IGKVI-6) | 2.6160 | 0.0251 |
| Annexin A4 (ANXA4) | 1.6041 | 0.0335 | Ig heavy variable 3-72 (IGHV3-72) | 2.2617 | 0.0442 | Ig heavy variable 2-24 (IGHV2-24) | 2.6444 | 0.0091 | Ig kappa variable 1-6 (IGKVI-6) | 2.3451 | 0.0298 |
| Ig lambda variable 6-57 (IGLV6-57) | 1.5958 | 0.0006 | Submaxillary gland androgen regulated protein 3A (SMR3A) | 2.2576 | 0.0445 | Glutamine-fructose-6-phosphate transaminase 1 (GPT1) | 2.4423 | 0.0159 | Apolipoprotein B (APOB) | 2.3173 | 0.0433 |
| Ig heavy variable 6-1 (IGHV6-1) | 1.3898 | 0.0002 | Mucin-like protein 1 (MUCL1) | 1.8144 | 0.0115 | Adipogenesis regulatory factor (ADIRF) | 2.3268 | 0.0216 | Ig lambda Like polypeptide 5 (IGLL5) | 2.1285 | 0.0216 |
| Ig kappa variable 1-27 (IGKV1-27) | 1.3662 | 0.0041 | Ig lambda variable 2-18 (IGLV2-18) | 1.8029 | 0.0174 | Ig kappa variable 6D-21 (IGKV6D-21) | 2.3009 | 0.0231 | Ig heavy variable 6-1 (IGHV6-1) | 1.9338 | 0.0158 |
| Ig kappa variable 3D-15 (IGKV3D-15) | 1.3271 | 0.0076 | Fibronectin 1 (FN1) | 1.6470 | 0.0318 | Ig heavy variable 2-5 (IGHV2-5) | 2.1339 | 0.0351 | Chaperonin containing TCP1 subunit 6A (CCT6A) | 1.9081 | 0.0271 |
| Endophilin-A3 (SH3GL3) | 1.2315 | 0.0018 | Ig kappa variable 1-27 (IGKV1-27) | 1.5837 | 0.0074 | Arginine-tRNA ligase (RARS) | 2.0840 | 0.0036 | Coagulation factor V (F5) | 1.5672 | 0.0298 |
| Cystatin-SN (CST1) | 1.2112 | 0.0213 | Ig lambda constant 3 (IGLC3) | 1.4769 | 0.0358 | Filaggrin (FLG) | 3.5306 | 0.0365 | Filaggrin (FLG) | 1.8535 | 0.0050 |
| Ig lambda variable 8-61 (IGLV8-61) | 1.1692 | 0.0068 | Ig lambda variable 2-18 (IGLV2-18) | 1.8719 | 0.0090 | Ig heavy variable 3-7 (IGHV3-7) | 1.6702 | 0.0276 | Keratin 9 (KRT9) | 1.2178 | 0.0054 |

| Down-regulated proteins | 1 week | 1 month | 3 months | 6 months | 12 months |
|------------------------|--------|---------|----------|----------|----------|
| Protein Name           | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value | Protein Name | Log₂ FC | P Value |
| Filaggrin (FLG) | -4.1638 | 0.0016 | Filaggrin (FLG) | -3.3967 | 0.0100 | Filaggrin (FLG) | -3.3168 | 0.0011 | Filaggrin (FLG) | -4.6876 | 0.0005 |
| Hexosaminidase subunit alpha (HEXA) | -3.0295 | 0.0112 | OTU deubiquitase, ubiquitin aldehyde binding 1 (OTUB1) | -2.9543 | 0.0173 | Actin related protein 3 (ACTR3) | -1.9630 | 0.0061 | Filaggrin (FLG) | -3.5306 | 0.0365 |
| Interleukin 19 (IL19) | -2.9780 | 0.0122 | Caspase 14 (CASP14) | -2.6177 | 0.0269 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) | -1.0129 | 0.0047 | Coronin 1A (CORO1A) | -1.8676 | 0.0196 |
| Superoxide dismutase 3 (SOD3) | -1.5974 | 0.0384 | S100 calcium binding protein A7 (S100A7) | -1.7365 | 0.0270 | Small proline-rich protein 3 (SPRR3) | -0.8491 | 0.0266 | Proteinase 3 (PRTN3) | -1.3437 | 0.0159 |
| Syndecan-1 (SDC1) | -1.3405 | 0.0308 | BAF nuclear assembly factor 1 (BANF1) | -1.6998 | 0.0211 | Transforming protein RhoA (RHOA) | -1.5814 | 0.0302 | (continued on next page)
were also observed (Fig. 4A, B). At 3 months, proteins playing a role in complement (IGKV3D-15, IGKV6D-21, IGLV5-45, and IGLV2-18) and wound healing (arginine-tRNA ligase (RARS), log2FC = 2.08) were expressed at a significantly higher level than baseline. At 6 months, significantly up-regulated proteins included APOB (log2-FC = 2.32) and various types of immunoglobulins (Table 2). At 1 year, immunoglobulin production reaction was still observed, and significantly altered proteins associated with endopeptidase activity (MUC5AC, log2FC = 1.97; CST5, log2FC = 1.80) and platelet degranulation (coagulation factor-V (F5), log2FC = 1.57) were emerged (Fig. 4). Filaggrin (FLG) was significantly downregulated in all time points after LASIK (Table 2).

Tear protein comparison between LASIK and SMILE

Before surgery, the tear protein profiles were comparable between the SMILE and LASIK groups (Fig. 5A). The comparisons of tear proteomic profiles following LASIK and SMILE are summarized in Table 3 and Fig. 5, 6. In the early postoperative period, the post-LASIK eyes contained significantly upregulated peptidylprolyl cis-trans isomerase B (PPIB, log2FC = 0.94) that is involved in wound healing, HSPA13 (log2FC = 1.36) in apoptosis, IGHV2-5 (log2FC = 2.39) in humoral immune reaction, cadherin 1 (CDH1, log2FC = 1.12) in leukocyte migration, and CST2 (log2FC = 2.06) in negative regulation of hydrolase activity. Thereafter, superoxide dismutase protein (superoxide dismutase (SOD2), log2FC = 1.01 at 3 months; log2FC = 1.46 at 6 months) and endoplasmic reticulum resident protein 29 (ERP-29, log2FC = 3.45 at 6 months) were significantly up-regulated in the LASIK group. At 1 year, the LASIK eyes had a significantly higher level of Rho GDP-dissociation inhibitor 1 (log2FC = 0.90) involved in extracellular structure organization, while FLG, MUCL1 and a lacrimal gland-abundant protein, proline-rich 4 (PRR4) were significantly lower (log2FC = -1.61, log2FC = -2.00 and log2FC = -1.43, respectively). In particular, the fold changes of tear MUCL1 level were negatively correlated with TBUT ($r = -0.47$, $P = 0.04$) (see Fig. 6).

Pathway analysis using the Reactome database showed similar findings: LASIK surgery was associated with significantly enriched biological processes involving the immune system, DNA replication, cell cycle, programmed cell death, hemostasis, and protein metabolism, compared to SMILE (Supplementary Figs. 2–4 and Supplementary Tables 2–4).

Tear neuromediator profiles

After LASIK surgery, the NGF level was elevated throughout the study period of 1 year, whereas this elevation was only observed for the initial 1 month after SMILE. There was a significant difference in the tear NGF level between the 2 groups at all time points (all $P < 0.05$). The substance P level was increased postoperatively in the LASIK group, whereas it did not change significantly in the SMILE patients. A significant difference was noted at 1 and 3 months ($P = 0.02$ for both; Table 4). The postoperative CGRP levels remained at a constant range for both surgeries. Overall, there was a significant but only moderate correlation between the tear substance P level and TBUT ($r = -0.49$, $P = 0.02$). There was no significant correlation between other clinical dry eye outcomes and tear neuromediators.

Discussion

In the present study, we characterized detailed tear proteomic profiles following SMILE and LASIK over a 1-year postoperative period. The tear neuromediator profiles were also investigated and correlated to clinical dry eye outcome measures. Significant
differences in the TBUT and tear substance P level were observed between 2 groups for the initial 3 months after surgery, whereas the differences in the tear NGF level and levels of other proteins, such as proteins involved in complement and coagulative cascades and extracellular structural organization, between 2 groups, were still noted at 1 year. To our knowledge, this is the first study comparing SMILE and LASIK from a proteomic perspective, using a high-sensitivity SWATH-MS technique. The results give a better understanding of the underlying pathophysiological alterations on a molecular level accounting for the clinical ocular surface changes postoperatively. The randomized trial design, as well as the use of data of paired eyes from the same patient, provided more accurate comparison by minimizing the inter-individual and inter-eye variation as well as selection bias.

The SWATH-MS technology is emerging as a preferred tool for clinical proteomic studies with a large number of samples involved, especially when analyzing limited volume of samples for multiple time points [13]. Our group has previously used this method to document the tear protein changes in patients with thyroid eye diseases and keratoconus [17,18]. Our data showed that during the first month postoperatively, the complement activation and immunoglobulin production were the dominant responses shown in both SMILE and LASIK. From postoperative 3 months onwards, while the immunological response persisted, cellular metabolic processes were also up-regulated. A higher level of apolipoproteins (APOC1, APOC3, and APOE), immunoglobulin family, proteins involved in complement cascade and FN1 were detected in the operated eyes in both groups, compared to the pre-operative baseline. Apolipoproteins participate in lipoprotein metabolism and have immune-regulatory functions [25]. APOC1 is a pro-inflammatory protein and positively correlates with IL-6 level [25]. APOE regulates macrophage function and enhances lipid antigen presentation by CD1 molecules to natural killer T cells [26]. Higher expression of APOE and APOC3 in aqueous has been reported in patients with open-angle glaucoma or exfoliative glaucoma due to more disrupted blood-aqueous barrier compared to normal subjects [27]. It is not surprising that tear FN1 also was elevated following surgery, as it has an important role in wound healing, depositing at the incision site and providing a guide for cell attachment and migration [28].

Three to six months following surgery, up-regulated expression of different types of immunoglobulins was observed in both SMILE and LASIK groups, whereas FLG and SMR3A were the top down-regulated proteins in both groups. FLG is expressed in the basal layer of corneal epithelium [29] and its function is to compensate for ocular surface stress [30]. Reduced expression of FLG has been reported in patients with atopic dermatitis-related keratitis due to the chronic ocular surface inflammation [29]. Similarly, the down-regulation of FLG in our study could be the consequence of surgery-induced inflammation. Similar results of reduced SMR3A in post-SMILE eyes were observed in the analysis of salivary glands in patients with primary Sjogren syndrome [31]. At 1 year, proteins modulating tear endopeptidase function, including goblet cell-derived mucin proteins (MUC1 and MUC5AC) and cystatin D protein (CST5), were expressed at significantly higher levels than the baseline in both groups. Tissue endopeptidase are involved in wound remodeling in response to tissue stress [32,33], and its expression has been shown to be increased in dry eyes [32]. The tear film on the ocular surface epithelia is maintained by mucins on its surface as well as by membrane-associated mucins in the apical cell surface [34]. MUC5AC has been considered as a potential marker for dry eye [34]. Its level in tears was positively correlated with the corneal staining in contact lens users and post-menopausal dry eye patients ($r = 0.37–0.53$) [35,36]. High expres-
sion of MUC1 was found in patients with dry eye or meibomian gland dysfunction (MGD), with correlation observed between its concentration and corneal staining as well as dry eye symptom questionnaire [36,37]. The elevated tear MUC1 and MUC5AC levels presented in our study could be a compensatory response and attributable to post-refractive surgery-related neurogenic keratopathy. MUC1 plays a major role in ocular surface lubrication, apical surface barrier, and osmo-sensing [38]. We found that the tear MUC1 level was significantly correlated with TBUT. The potential of the use of MUC1 as an indicator for the evaluation of tear film stability after refractive surgery warrants further investigation.

We subsequently compared the tear proteomes between SMILE and LASIK procedure (Table 3). In the first month, the differentially regulated tear proteins in LASIK showed a significantly greater humoral immune response, wound healing, apoptosis, negative regulation of hydrolase activity, and leukocyte migration. We found that the protein contents had significant variation at 1 week after surgery, and this could be due to the use of postoperative topical steroids that affected the ocular response and tear protein profiles. At 1 month, CST2 and HSPA13 were among the top 5 up-regulated tear proteins observed in LASIK compared to SMILE. The CST family are cysteine protease inhibitors and exert direct immunomodulatory properties [39]. Previous studies have observed up-regulation of CST1 in eyes following femtosecond laser-assisted LASIK at 1 week [40], and down-regulation of CST4 in patients with dry eye and MGD [41]. CST5 was down-regulated in hard and soft contact lens users [42], but was significantly increased in patients after brain injury, similar to the change in the present study that CST5 levels increased after surgical injury [43], regardless of the surgical types. HSPA13 belongs to HSP70 family [44], which is ubiquitously expressed during cell stress, and is involved in T cell regulation in various inflammatory conditions, such as the retinal laser photocoagulation [44]. Given the nature of the larger incision and excimer photoablation involved in LASIK, it could be anticipated that the activation of HSP would be more intensive in response to more extensive tissue reaction in LASIK than SMILE [45]. Significantly higher expression of SOD2 was observed following LASIK after 3 months. The increase in SOD2 could be a feedback response to the greater tissue reshaping from LASIK, to facilitate the clearance of reactive oxygen species and inflammatory cytokines [46].

In the later postoperative period (6 to 12 months), ERP29 and KRT18 were the two most over-expressed proteins in the LASIK compared to SMILE group, while the clinical dry eye parameters had become comparable between 2 groups. Up-regulation of
### Table 3

Top 10 up-regulated and down-regulated tear proteins comparing post-LASIK versus post-SMILE eyes at different time points postoperatively.

|                | 1 week |          | 1 month |          | 3 months |          | 6 months |          | 12 months |          |
|----------------|--------|----------|---------|----------|----------|----------|----------|----------|----------|----------|
| **Up-regulated** |        |          |         |          |          |          |          |          |          |          |
| Protein Name   | Log2 FC | P Value  | Protein Name | Log2 FC | P Value  | Protein Name | Log2 FC | P Value  | Protein Name | Log2 FC | P Value  |
| Keratin 5 (KRT5)             | 1.2390 | 0.0280 | Ig heavy variable 2–5 (IGHV2-5) | 2.3930 | 0.0278 | Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) | 1.1398 | 0.0096 | Endoplasmic reticulum resident protein 29 (ERP29) | 3.4489 | 0.0091 |
| Cadherin-1 (CDH1)             | 1.1240 | 0.0462 | Cystatin-SA (CST2) | 2.0569 | 0.0491 | Superoxide dismutase (SOD2) | 1.0080 | 0.0220 | S-methyl-5'-thioadenosine phosphorylase (F1TAP) | 2.2605 | 0.0464 |
| Peptidyl-prolyl cis-trans isomerase B (PPIB) | 0.9430 | 0.0309 | Heat shock 70 kDa protein 13 (HSPA13) | 1.3550 | 0.0456 | Ig lambda constant 3 (IGL3) | 0.8751 | 0.0467 | Plastin-2 (LCP1) | 2.2162 | 0.0495 |
| Cellular repressor of E1A stimulated gene 1 (CREG1) | 1.1145 | 0.0093 | Keratin 7 (KRT7) | 0.7884 | 0.0385 | Tumor protein D52 (TPD52) | 1.7152 | 0.0228 | Keratin 7 (KRT7) | 1.1975 | 0.0021 |
| Neuroserpin (SERPIN1) | 0.9644 | 0.0166 | Keratin 2 (KRT2) | 0.7235 | 0.0201 | Superoxide dismutase 2 (SOD2) | 1.4622 | 0.0424 | Keratin 13 (KRT13) | 0.9256 | 0.0143 |
| Phospholipid transfer protein (PLTP) | 0.9164 | 0.0446 | CD44 antigen (CD44) | 0.8495 | 0.0347 | Alcohol dehydrogenase class 4 mu/sigma chain (ADH7) | 1.2539 | 0.0277 | Transaldolase (TALDO1) | 0.8651 | 0.0349 |
| Cathepsin D (CTSD) | 0.5876 | 0.0235 |             |          |          |          |          |          |          |          |
| Serum amyloid A-4 protein (SAA4) | −3.1164 | 0.0014 | Keratin 18 (KRT18) | −2.2235 | 0.0352 | Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit 8 alpha isoform (PPP2R2A) | −2.3558 | 0.0020 | Filaggrin (FLG) | −2.4520 | 0.0351 |
| Apolipoprotein C-I (APOC1) | −3.0195 | 0.0020 | Keratin 4 (KRT4) | −1.2640 | 0.0129 | Barrier-to-autointegration factor (BANF1) | −1.6611 | 0.0293 | Fibronectin (FN1) | −1.5303 | 0.0352 |
| DNA-(apurinic or apyrimidinic site) lyase (APEX1) | −2.1237 | 0.0297 | Keratin 13 (KRT13) | −1.2336 | 0.0073 | Phosphoglucomutase-1 (PGM1) | −1.6352 | 0.0319 | Ig lambda constant 3 (IGL3) | −1.3581 | 0.0162 |

(continued on next page)
ERP29 facilitates DNA and tight junction repair, extracellular matrix homeostasis and oxidative stress clearance, and ERP29 may also act as a neuroprotectant [47]. We speculate that ERP29 up-regulation might be feedback to the greater tissue modification and response in LASIK. PRR4 is a lacrimal gland-secreted protein and was down-regulated in the post-LASIK eyes, compared to post-SMILE eyes, at 1 year. PRR4 was found to be decreased in patients with dry eye syndrome, and this decrease was correlated with the severity of clinical symptoms [48]. The down-regulation of PRR4 in the LASIK group may imply that the lacrimal neural arc reflex originating from the corneal nerves was still impaired at 1 year, and had greater impairment in the LASIK group, although the clinical dry eye signs had returned to the preoperative level and were comparable between 2 procedures. Similarly, a previous study on the evaluation of the effects of LASIK on tear proteomes showing that eyes with a larger flap were associated with reduced expression of lacrimal gland proteins due to greater corneal nerve damage [40].

We noted that the tear proteomic expression was somewhat different from that in patients with idiopathic dry eye syndrome [41,49,50]. This might be due to two reasons. Firstly, the pathogenesis and ocular surface changes resulting from refractive surgery and subsequent wound healing are neurogenic and neuro-inflammatory reaction-related, which are essentially different from those of idiopathic dry eye. This was also reported in our previous study showing that the tear proteome after LASIK was different from that reported in patients with idiopathic dry eye [40]. Secondly, the postoperative regimen, consisting of corticosteroids and antibiotics, would also alter the initial protein expression. These eye drops were given during the early postoperative period, when the most pronounced pathophysiological process occurred.

We were also interested in the changes of neuromediator profiles following surgery as these are related to the postoperative corneal reinnervation and have not been investigated in SMILE. The neuromediators are released by corneal nerves and maintain the function and integrity of corneal epithelial and stromal kerocytes [51], and they in turn regulate the maintenance, regeneration and integration of nerve function [51,52]. The effects of NGF on promoting corneal wound healing have drawn considerable attention. NGF participates in ocular surface homeostasis by producing neurotrophins and facilitating sensory dependent corneal and tearing reflex [51]. Our results showed that, in the same patient, the NGF level in the post-LASIK eyes was significantly higher than in the post-SMILE eyes even 1 year after surgery. The level returned to the preoperative range at 1 month in SMILE, while it was persistently high in LASIK. After surgery, the pro-inflammatory and inflammatory cytokines amplify the expression of NGF to be released from the corneal epithelial cells and kerocytes [53]. The more extensive disruption on the cornea by LASIK results in more severe tissue stress, inflammation and greater wound healing responses, which have been demonstrated in our SWATH-MS proteomic results and our previous work comparing these two procedures using animal models [45,54]. The differences in the tissue responses could explain the differences in the NGF level. Similarly, Lee et al. presented the tear NGF concentrations were significantly higher in photorefractive keratectomy than LASIK [11].

Substance P and CGRP are the most abundant neuropeptides in corneas and are considered as the main triggers of neurogenic inflammation [55]. We observed that the tear substance P level increased significantly for 3 months following LASIK but did not in the SMILE group. This is in agreement with a study reporting an increase in substance P level in post-LASIK eyes at 3 months [56], but we further demonstrated this increase lasted for 1 year. In addition, our results showed the tear CGRP concentration did
not change after either LASIK or SMILE. This is consistent with a previous study presenting the CGRP level did not differ from the baseline to 3 months [56]. However, another study reported that the CGRP level was significantly higher in LASIK than controls at 1 year [8]. This disparity may come from the femtosecond laser system used in the surgery. The Intralase system (Abott Medical Optics, Santa Ana, CA, USA) employs a lower repetition rate but higher laser energy, while the Visumax system, the platform used in the present study, uses a higher repetition rate and lower laser energy [40]. The former applies the suction on the conjunctiva and sclera, which may stimulate the goblet cells to release CGRP [51], whereas the latter generates the suction only on the cornea via a smaller cone. Following SMILE, the substance P and CGRP concentrations did not change significantly.

Our RCT data on dry eye variables showed that the difference between the 2 procedures was noted for the initial 1 month for corneal staining, and 3 months for the TBUT, with more favorable outcomes in SMILE. There was no difference in the Schirmer’s test results. A systematic review has also demonstrated similar trends, although some studies reported differences in TBUT might be present until 6 months [2,3]. A significant but only moderate correlation was observed between the substance P level and TBUT, and no correlation was found between other dry eye parameters and neuromediators. This suggests that the current clinical assessment for

---

### Table 4

|                     | Pre-op | 1 week | 1 month | 3 months | 6 months | 12 months |
|---------------------|--------|--------|---------|----------|----------|-----------|
| **NGF (pg/ml)**     |        |        |         |          |          |           |
| SMILE               | 36.8 ± 16.3 | 37.1 ± 18.2 | 42.5 ± 14.7 | 37.6 ± 23.4 | 38.0 ± 19.8 | 36.2 ± 11.6 |
| LASIK               | 35.9 ± 15.6 | 40.5 ± 18.5 | 54.4 ± 17.2 | 44.0 ± 19.4 | 45.2 ± 20.8 | 41.4 ± 24.7 |
| P value             | 0.77    | 0.047  | <0.01   | 0.04     | <0.01    | 0.01      |
| **Substance P (pg/ml)** |      |        |         |          |          |           |
| SMILE               | 1940.0 ± 647.3 | 1900.4 ± 773.5 | 1858.3 ± 828.4 | 1833.1 ± 890.7 | 1893.1 ± 693.0 | 1956.4 ± 818.5 |
| LASIK               | 1874.0 ± 652.4 | 1962.0 ± 618.5 | 2157.1 ± 792.5 | 2156.4 ± 803.5 | 1998.2 ± 682.0 | 2114.9 ± 756.2 |
| P value             | 0.68    | 0.78   | 0.04    | 0.04     | 0.74     | 0.88      |
| **CGRP (ng/ml)**    |        |        |         |          |          |           |
| SMILE               | 3.7 ± 1.3 | 3.6 ± 0.9 | 3.6 ± 1.2 | 3.5 ± 1.4 | 3.7 ± 0.9 | 3.9 ± 1.1 |
| LASIK               | 3.8 ± 1.4 | 3.8 ± 1.2 | 3.7 ± 1.0 | 3.9 ± 1.5 | 4.0 ± 1.8 | 4.0 ± 0.9 |
| P value             | 0.79    | 0.85   | 0.84    | 0.74     | 0.71     | 0.75      |

---

Fig. 6. Chord plots demonstrating GO analysis of top 10 up-regulated and down-regulated protein profiles when comparing LASIK versus SMILE procedure at 1 week (A), 1 month (B), 3 months (C) and 12 months (D). Chord plots show the clustering of the expression profiles. Log FC: log2 (fold-changes).
Financial Support

This work was supported by the HREF grant, Singapore National Eye Centre, Singapore (R1568/67/2018).

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jare.2020.11.001.

References

[1] Liu YC, Rosman M, Mehta JS. Enhancement after small-incision lenticule extraction: Incidence, risk factors, and outcomes. Ophthalmology 2017;124(6):813–21.
[2] Kobash H, Kamiya K, Shimizu K. Dry eye after small incision lenticule extraction and femtosecond laser-assisted LASIK: Meta-analysis. Cornea 2017;36(1):85–91.
[3] Denoyer A, Landman E, Trinh L, Faure JF, Aucin F, Baudouin C. Dry eye disease after refractive surgery: comparative outcomes of small incision lenticule extraction versus LASIK. Ophthalmology 2015;122(4):669–76.
[4] Fuest M, Mehta JS. Iatrogenic dry eye following cataract and refractive surgical procedures. In: He MG, editor. Ocular surface diseases, disorders, & dysfunctions. NJ: Halio: Thorofare; 2016. p. 3–6.
[5] Liu YC, Tan DTH, Mehta JS. Wound healing after ReLEx surgery. In: Sekundo W, editor. Laser in situ keratomileusis in the treatment of refractive errors. Elsevier: Amsterdam; 2009. p. 179–206.
[6] Yam GH, Fuest M, Zhou L, Liu YC, Deng L, Chan AS, et al. Differential epithelial protein changes. Due to limited tear protein amount, the high-sensitivity proteomic techniques are used to detect fine protein changes. To limited tear protein amount, the SWATH-MS and ELISA experiments were conducted in two different cohorts. Hence, we could not explore the link between the tear neuromediator profiles and SWATH-MS data in this study. Tear collection using a microcapillary, rather than a Schirmer's strip, may ensure a higher protein concentration to be collected. For studies on surgical techniques, the inherent limitation is a double-masked study design is not possible as the surgeon performed the surgery and investigators could differentiate the surgical type with slit lamp during the assessments, for example, during the dry eye assessments in this study. Subjective evaluation on dry eye symptoms, such as questionnaires, would be considered to improve the study objectivity. Validation experiments on selected up- and down-regulated proteins using an additional cohort should be considered. Future studies will include analysis on the corneal nerve plexus imaged by in vivo confocal microscopy to illustrate the relationship between the tear neuromediators and corneal nerve metrics, and to identify potential biomarkers for the severity of corneal denervation and the status of nerve regeneration following refractive surgery [57].

Conclusions

We have identified the proteomic response following SMILE and LASIK. Over a one-year postoperative period, there were some similar responses observed in these two procedures. However, there was significantly higher tear NGF level, as well as up-regulated leukocyte migration, humoral immune response wound healing, apoptotic, and endopeptidase activities, and down-regulated lacrimal gland-abundant protein, in the post-LASIK eyes. These results indicate that different proteomic profiles were still observed even though clinical dry eye evaluation findings became comparable between these 2 procedures. Tear protein science is an evolving area, and current evidence has suggested that tear proteins have a role in modifying clinical practice [34]. This is the first study to demonstrate the detailed proteome changes of SMILE and LASIK. Our data provide new insights into the biological responses on the ocular surface after refractive surgery.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

Nil.
Allan LL, Hoefl K, Zheng DJ, Chung BK, Kozak FK, Tan R, et al. Apolipoprotein-

Berry M, Pult H, Purslow C, Murphy PJ. Mucins and ocular signs in

Chao C, Stapleton F, Zhou X, Chen S, Zhou S, Golebiowski B. Structural and

Manicam C, Perumal N, Wasielica-Poslednik J, Ngongkole YC, Tschabunin A,

Gipson IK, Spurr-Michaud SJ, Senchyna M, Ritter 3rd R, Schaumberg D.

Mohamed-Noriega K, Riau AK, Lwin NC, Chaurasia SS, Tan DT, Mehta JS. Early

Lambiase A, Micera A, Sacchetti M, Cortes M, Mantelli F, Bonini S. Alterations of

D'Souza S, Petznick A, Tong L, Hall RC, Rosman M, Chan C, et al. Comparative

Corrales RM, Narayanan S, Fernandez I, Mayo A, Galarrreta DJ, Fuentes-Paez G,

Lim RR, Tan A, Liu YC, Barathi VA, Mohan RR, Mehta JS, et al. ITF2357

Zhou L, Beuerman RW, Chan CM, Zhao SZ, Li XR, Yang H, et al. Identification of

Liu YC, Ang HP, Teo EP, Lwin NC, Yang GH, Mehta JS. Wound healing profiles of

Liu YC, Jung ASJ, Chin JY, Yang LWY, Mehta JS, et al. Cross-sectional Study on Corneal

Fabian TK, Hermann P, Beck A, Fejerdy P, Fabian G. Salivary defense proteins:

Inoue T, Kawaji T, Tanihara H. Elevated levels of multiple biomarkers of

Lyu Q, Ludwig IS, Kooten PJS, Sijts A, Rutten V, van Eden W, et al. Leucinostatin

Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L. Nerve growth factor

Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115(20):3861–3

Hill LJ, Di Pietro V, Hazeldine J, Davies D, Toman E, Logan A, et al. Cystatin D

McLaughlin T, Falkowski M, Wang JJ, Zhang SX. Molecular Chaperone ERp29: A

Ko HL, Wang YS, Fong WL, Chi MS, Chi KH, Kao SJ. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer 2014;5(6):500–8.

Allan LL, Hoefl K, Zheng DJ, Chung BK, Kozak FK, Tan R, et al. Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood 2009;114(12):2411–6.

Josse T, Kawaji T, Tanihara H. Elevated levels of multiple biomarkers of Alzheimer’s disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci 2013;54(8):5353–8.

Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115(20):3861–3

Liu YC, Xu F, Wang X, Zhang Z, Zhao W, Li Z, et al. Identification of differentially expressed genes in primary Sjögren’s syndrome. J Cell Biochem 2019;120(10):17368–77.

Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012;130(1):90–100.

Liu YC, Ang HP, Teo EP, Lwin NC, Yan GH, Mehta JS. Wound healing profiles of hyperopic-small incision lenticule extraction (SMILE). Sci Rep 2016;6:29802.

Becuwe P, Ennen M, Klotz R, Barbiex C, Grandemange S. Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance. Free Radic Biol Med 2014;77:139–51.

McLaughlin T, Falkowski M, Wang JJ, Zhang SX. Molecular Chaperone ERp29: A potential target for cellular protection in retinal and neurodegenerative diseases. Adv Exp Med Biol 2018;1074:421–7.

Aluru SV, Agarwal S, Srinivasan B, Iyer GK, Rajappa SM, Tatu U, et al. Lacrimal proline rich 4 (LPR4) protein in the tear fluid is a potential biomarker of dry eye syndrome. PLoS ONE 2012;7(12):e51979.

Jung JH, Ji YW, Hwang HS, Oh JW, Kim HC, Lee HK, et al. Proteomic analysis of human lacrimal and tear fluid in dry eye disease. Sci Rep 2017;7(1):13363.

Zhou L, Beuerman RW, Chan CM, Zhao SZ, Li XR, Yang H, et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res. 2009;8(11):4889–905.

Al-Aqaba MA, Dhillon VK, Mohammed I, Said DG, Dua HS. Corneal nerves in patients with or without atopic dermatitis. Int Arch Allergy Immunol 2019;163(1):20–4.

Binz T, Jakobsson E, Stenman T, Arvidsson K, Pettersson U, et al. Identification of tear film characterization in dry eye and meibomian gland dysfunction. J Proteome Res. 2009;8(11):4889–905